ADMA Biologics (ADMA) Stock Price, News & Analysis

Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Key Stats

• Today's Range: $20.87 to $21.70
• 50-Day Range: $15.62 to $22.62
• 52-Week Range: $3.60 to $23.64
• Volume: 2.19 million shs
• Average Volume: 3.64 million shs
• Market Capitalization: $5.04 billion
• P/E Ratio: 76.07
• Dividend Yield: N/A
• Price Target: $21.25
• Consensus Rating: Buy

ADMA Biologics Stock Analysis - MarketRank™

ADMA Biologics scored higher than 67% of companies evaluated by MarketBeat, and ranked 364th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Buy

Consensus Rating

ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ADMA Biologics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 50.00%

Earnings Growth

Earnings for ADMA Biologics are expected to grow by 50.00% in the coming year, from $0.52 to $0.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADMA Biologics is 76.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADMA Biologics is 76.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.48.

Price to Book Value per Share Ratio

ADMA Biologics has a P/B Ratio of 21.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.43% of the outstanding shares of ADMA Biologics have been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ADMA Biologics has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADMA Biologics does not currently pay a dividend.

Dividend Growth

ADMA Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.43% of the outstanding shares of ADMA Biologics have been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ADMA Biologics has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.64

News Sentiment

ADMA Biologics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for ADMA Biologics this week, compared to 6 articles on an average week.

Search Interest

55 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

Only 22 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,224,121.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of ADMA Biologics is held by insiders.

Percentage Held by Institutions

75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADMA Stock Analysis - Frequently Asked Questions

How have ADMA shares performed this year?

ADMA Biologics' stock was trading at $4.52 at the start of the year. Since then, ADMA stock has increased by 371.2% and is now trading at $21.30.
View the best growth stocks for 2024 here.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The biotechnology company earned $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a trailing twelve-month return on equity of 53.20% and a net margin of 17.80%.

Who are ADMA Biologics' major shareholders?

ADMA Biologics' top institutional shareholders include State Street Corp (5.58%), Geode Capital Management LLC (2.31%), Two Sigma Advisers LP (1.91%) and Assenagon Asset Management S.A. (1.50%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Lawrence P Guiheen and Bryant Fong.
View institutional ownership trends.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADMA
• CUSIP: N/A
• CIK: 1368514
• Web: www.admabiologics.com
• Phone: (201) 478-5552
• Fax: 201-478-5553
• Employees: 530
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.25
• High Stock Price Target: $26.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: -0.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.28
• Trailing P/E Ratio: 76.07
• Forward P/E Ratio: 40.96
• P/E Growth: N/A
• Net Income: $-28,240,000.00
• Net Margins: 17.80%
• Pretax Margin: 19.16%
• Return on Equity: 53.20%
• Return on Assets: 26.07%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 7.09
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $258.21 million
• Price / Sales: 19.50
• Cash Flow: $0.05 per share
• Price / Cash Flow: 405.96
• Book Value: $0.98 per share
• Price / Book: 21.73

Miscellaneous

• Outstanding Shares: 236,390,000
• Free Float: 227,644,000
• Market Cap: $5.04 billion
• Optionable: Optionable
• Beta: 0.64